Search

The association between AIDS and cancer was recognized from the beginning of the AIDS epidemic, when the appearance of Kaposi sarcoma in a cluster of young men was one of the first signs of this new disease. It was soon recognized that AIDS was caused by infection with a novel virus (HIV) and that AIDS patients are prone to develop a number of “AIDS-defining” cancers: Kaposi sarcoma, lymphoma, and cervical cancer. The development of effective combination anti-HIV therapy starting around 1996 converted AIDS from a death sentence to a manageable disease and led to dramatic shifts in the epidemic. As this therapy was able to improve immune function in patients, the incidence of most “AIDS-defining” cancers decreased. There is a misconception, however, that AIDS has gone away. In fact, as AIDS patients are living longer, the number of AIDS patients has more than doubled in the United States since 1996, and the AIDS population overall has increased in age. Also, as AIDS patients are less likely to die of other complications, cancer is coming to the forefront as one of the most common causes of death in regions where AIDS drugs are widely available. Moreover, the three “AIDS-defining” cancers are now taking a back seat to a number of other HIV-associated cancers, such as Hodgkin lymphoma, lung cancer, and anal cancer. In the developing world, AIDS-associated cancers are a major public health problem, and in some regions of sub-Saharan Africa, Kaposi sarcoma is the most common tumor in men.In recent years, there has been a vast increase in our understanding of HIV-associated cancers. We now know, for example, that most are caused by other viruses and that the main role of HIV and immunodeficiency is to provide a supportive environment for the viruses to multiply and for the cancers to develop. But there remain a number of unanswered questions and a need for improved prevention and therapy. In the 28 chapters of this book, written by some of themost renowned experts in this field, we present up-to-date information on the cancers associated with HIV infection. The chapters cover the epidemiology of these cancers, their pathogenesis, their clinical presentation, and their treatment. The book will be of value to physicians, other medical professionals, students, and researchers with an interest in AIDS, viral-associated cancers, or HIV-associated malignancies.TABLE OF CONTENTS1. HIV-associated Cancers: OverviewRobert Yarchoan, Thomas Uldrick, Mark Polizotto2. Epidemiology of AIDS-defining MalignanciesWilliam A. Blattner and Rebecca G. Nowak3. Epidemiology of non-AIDS Defining MalignanciesAndrew E. Grulich4. HIV Cancers in Resource-Limited RegionsSam M. Mbulaiteye5. Kaposi's Sarcoma-associated Herpesvirus (KSHV)Blossom Damania and Dirk P. Dittmer6. Epstein Barr Virus (EBV)Lindsey Hutt-Fletcher7. Human Papillomavirus (HPV)Zhi-Ming Zheng8. Merkel Cell Polymavirus (MCV)Nicole Fischer and Adam Grundhoff9. Presentation and Pathogenesis of Kaposi's SarcomaCorey Casper10. Management of Kaposi's SarcomaSusan E. Krown11. Presentation and Pathogenesis of HIV LymphomasRichard F. Little, Stefania Pittaluga, Kieron Dunleavy12. Diffuse Large B-Cell LymphomaNeel K. Gupta and Lawrence D. Kaplan13. Burkitt and Burkitt-Like LymphomaKishor Bhatia and Sam M. Mbulaiteye14. Primary Effusion LymphomaGiovanna Tosato15. AIDS-related Central Nervous System Lymphoma Jan Davidson-Moncada and Thomas Uldrick16. Plasmablastic and Other LymphomasHuan-You Wang, Ida Wong-Sefidan, Erin Reid17. Hodkin LymphomaMichele Spina, Rosanna Ciancia, Accursio Augello18. Multicentric Castelman DiseaseMark N. Polizzotto, Thomas S. Uldrick, Robert Yarchoan19. CervicalCancerElizabeth A. Stier

The Reticuloendothelial (RE) Society, which is concerned with advd~cement of knowledge concerning the many diverse functions of RE cells, organizes national and international meetings and publishes a scientific journal. The VIII International Congress of the RE Society was held in Jerusalem, Israel, June 18-23, 1978. The Congress had as its scientific objec,tive a wide range of sub­ jects concerning the RE System, especially as related to macro­ phage function and interaction with lymphocytes. Emphasis of the Congress was placed on the nature and function of macrophages and other cells of the RE System with reference to immune responses, anti-infectious activity, tumor immunity, autoimmunity, and trans­ plant rejection. The secretion of soluble factors by rnacrophages and lymphocytes and the mode of action of these factors on other cells was stressed. During the Congress some discussion was entertained concerning the controversy as to what constitutes the'RE System'per se. Some investigators feel that the phagocytic activity of rnacrophages is the most important aspect of the RE System playing also a major role in many parameters of immunity. Mononuclear phagocytes include tissue rnacrophages as well as cir­ culating monocytes and their precursors. Although phagocytosis is a major functional activity of these cells, it is only one of several activities.

Profitieren Sie von den rasanten Fortschritten in der klinischen Immunologie! Das deutschsprachige Standardwerk zur klinischen Immunologie wurde komplett neu bearbeitet, aktualisiert und erweitert. Der Fokus liegt dabei auf den klinischen Aspekten auch seltenerer Krankheitsbilder, die durch viele Abbildungen und Fallberichte veranschaulicht werden. Highlights der 3. Auflage: Angeborenes und adaptives ImmunsystemAngeborene und erworbene ImmundefekteEntzündlich rheumatische SystemerkrankungenOrganbezogene AutoimmunopathienAllergische Krankheitsbilder Lymphoproliferative Syndrome, Gammopathien und LymphomeInformative Kasuisten

Physiological, pharmacological and molecular biological data generated over the past three decades have demonstrated the existence of two major families of extracellular receptors, the P1, a family of four G-protein coupled receptors and the P2, a family of at least 12 receptors responsive to purine (ATP, ADP) and pyrimidine (UTP) nucleotides through which adenosine and ATP can function as extracellular messengers. The present two-part volume represents an integrated compendium of invited chapters by leading researchers in the area focusing on advances in the understanding of purinergic and pyrimidinergic signaling systems, their role(s) in tissue function and pathophysiology and advances in developing potential new medications based on the modulation of P1 and P2 receptor signaling processes. The volumes will thus provide the reader with a topical, comprehensive and integrated overview of this important area.

During the past decade, the rapid growth of molecular and cellular knowledge of macrophages, as a specialized host defense and homeostatic system, has begun to offer attractive targets for therapeutic intervention. Macrophages play a central role in a wide range of disease processes, from genetically determined lysosomal storage diseases, to acute sepsis, chronic inflammation and repair, tissue injury and cell death. Under- or overactivity of macrophage clearance, immune effector functions and responses to metabolic abnormalities contribute to common disorders such as autoimmunity, atherosclerosis, Alzheimer's disease and major infections including AIDS and Tuberculosis. Whilst the goals of therapeutic intervention based on improved understanding of macrophage functions and their contribution to pathogenesis may seem self evident, there are considerable difficulties in producing useful new agents. The present volume covers a range of subjects and provides opportunities for a more focused macrophage-targeted approach. The individual chapters review selected topics briefly, to place cellular processes and molecular targets in perspective. Overall, the volume should provide a broad sample of the state of the art. Useful reviews and references in the literature are cited within individual chapters.

The goal of the International Immune-Mediated Diseases: From Theory to Therapy (IMD) Congress is to bring the best world immunologists and clinicians to Moscow to participate in plenary sessions, symposia and educational workshops designed to expose basic and clinical immunologist as well as practicing clinicians to the newest developments in the field. First IMD Congress consisted of 8 Plenary Sessions, 40 Symposia and 25 Workshops. The meeting attracted almost 2000 participants and speakers from 15 countries. After this great success of the First IMD Congress, the Organizing Committee decided to convene the meeting every other year and the Second International IMD Congress was planned for September 2007. Special attention will be given to innovative therapeutic modalities, allergy and asthma, immunodeficiency, tumor and transplant immunology, immunotherapy and vaccines, HIV and infectious diseases, autoimmune diseases, inflammation, immunomonitoring and immunodiagnostics. This volume includes contributions from the speakers of the Second IMD Congress (September 10-15, 2007; Moscow, Russia) who are eager to share some of the academic and clinical enthusiasm that defines the IMD meetings.

The rapid developments in immunology in recent immunomodulatory drugs can be distinguished years have dramatically expanded our knowledge of from their beneficial therapeutic effects. mammalian host defence mechanisms. The molecu- Currently,it is only possible to obtain an overview lar mechanisms of cellular interactions during of these various aspects of immunopharmacology immune responses have been unravelled,the intra- by reading a range of immunological,pharmacol- cellular responses involved in signal transduction ical,diagnostic and toxicological literature. Good delineated and an ever-increasing number of soluble immunological textbooks are available, while mediators of immune and inflammatory reponses immunopharmacology is covered mainly in terms of have been discovered. the inflammatory response. Principles of Immuno- The initial result of this explosion of knowledge pharmacology is intended to provide for the first time has been to provide the researcher and the clinician in a single volume a basic understanding of with an arsenal of diagnostic tools with which the immunological mechanisms,a review of important immunological bases of disease processes can be immunodiagnostic tools and a description of the investigated. This has made disease diagnosis much main pharmacological agents which modify the more precise,enabling the physician to tailor therapy immune response,together with an introduction to much more closely to the individual patient's needs. immunotoxicology. As such we hope that it will be However,better understanding of disease processes useful as a reference text for physicians,researchers only provides a gradual improvement in therapy. This and students with a rudimentary knowledge of is because the new molecular targets that have beenimmunology.

Although the potential for immunomodulation has been recognized for many years there has been an explosion of data in this field with relevance especially to the treatment of chronic airway diseases. Most of the work in this field has been conducted by Japanese investigators but in the last decade there has been a body of work outside of Japan that supports and enhances these findings. The book covers basic research like effects on bacteria, anti-inflammatory and mucoregulatory effects, but also clinical results with up-to-date information for the use of such medications to potentially treat diseases as diverse as chronic airway diseases, arthritis, inflammatory bowel disease, and cancer. The volume is intended for pulmonary physicians, researchers in inflammation research, and pharmaceutical companies interested in the development of such agents. It provides background information for the clinician as well as in depth exploration of cutting edge science.

'Natural Immunity'is a broadly-based account of the activities of the evolutionarily conserved molecules, cells and processes of the natural immune system. This encompasses the early host protection against microbes (bacteria and viruses) and tumours, prior to the generation of the adaptive immune response, diverse major current pathologies including inflammatory and autoimmune diseases, and key roles in essential physiological processes such as reproduction and wound healing. - The first comprehensive book on natural immunity - Reviews new topics, effects of behaviour, aging, and exercise, and diet on natural immunity - Highlights the physiological role of natural immunity - Focuses on the relationship of the neuroendocrine system with natural immunity - Brings together the diversity and complexity of natural immune system activity

In the past, neutrophils were often reduced to their ability to release preformed mediators and kill pathogens. The present volume of Chemical Immunology and Allergy, however, offers a very broad and timely view by highlighting the versatile functions of neutrophils in inflammatory, immune and antitumoral responses. Leading investigators uncover novel aspects of neutrophils, such as their capacity to control gene expression at the transcriptional level, or respond to proinflammatory cytokines, cytokine receptor chains (gc) and endogenous anti-inflammatory lipid mediators. Further points under discussion are neutrophils presenting antigens, activating T cells, participating in chemokine networking, and producing IL-12 and other cytokines during infectious diseases. Among the most original findings presented in this publication figure the observations that neutrophils cause increased vascular permeability during acute inflammation, regulate directly the angiogenic process, and influence tumor development. A final article offers a detailed description of the molecular processes affecting neutrophil cell death and survival. Unique in its field, this valuable volume is recommended reading not only for immunologists and pathologists, but also for cell biologists, hematologists and immunobiologists.